Prodromal symptoms in hidradenitis suppurativa

HS is a chronic inflammatory skin disorder marked by recurring nodules and scarring in intertriginous areas. While prodromal symptoms are commonly reported, no systematic studies have examined their nature or timing. Prior research has shown that HS affects quality of life through pain and scarring. This gap motivated a survey-based investigation to identify the range of symptoms preceding HS flares. No prior work had resolved the specific types or frequencies of these symptoms. This uncertainty drove the need for patient-reported data collection. Existing literature lacks clarity on whether these symptoms are consistent across individuals. The absence of formal studies on this topic limits treatment timing and efficacy. This uncertainty is particularly relevant for HS management strategies. Understanding prodromal patterns could improve early intervention opportunities.

The aim of this study was to explore the range and timing of symptoms that precede HS flare-ups. The specific problem addressed is the lack of formal data on prodromal symptoms in HS. The motivation stems from the potential to improve treatment timing and outcomes. By identifying these symptoms, clinicians may better anticipate flares. The study focused on patient-reported experiences rather than clinical observations. The goal was to quantify symptom frequency and timing relative to HS lesions. No prior work had systematically collected this information from HS patients. This approach could lead to more personalized treatment plans.

The study used a questionnaire administered to 72 HS patients to gather data on prodromal symptoms. The survey collected information on symptom frequency, type, and timing relative to HS flares. Patients were asked to report perceived associations between symptoms and flare-ups. The tool included open-ended and structured questions to capture variability. No control group was used, as the focus was on patient-reported experiences. Data were analyzed for patterns in symptom occurrence and timing. The questionnaire design allowed for both qualitative and quantitative insights. The approach emphasized capturing subjective experiences rather than objective measurements.

Of the 72 patients, 60 (83.3%) reported experiencing one or more prodromal symptoms before HS flares. The most common symptoms included fatigue (32%) and malaise (23%). Localized symptoms like skin erythema (75%) and paraesthesia (63%) were also frequently reported. Headache and nausea occurred in 11% and 2% of cases, respectively. Itching was reported in 20% of patients. The majority of symptoms occurred more than 24 hours before flare onset (45%). A smaller proportion (20%) experienced symptoms within 12–24 hours. These findings suggest a consistent pattern of pre-flare symptoms among HS patients.

The authors propose that HS patients commonly experience prodromal symptoms before flare-ups. These findings may guide earlier treatment decisions by dermatologists. The study suggests that fatigue and malaise are the most frequently reported symptoms. Localized symptoms like erythema and paraesthesia are also significant indicators. The timing of symptoms, often more than 24 hours before flare onset, is notable. The authors suggest that these findings could improve HS management strategies. No prior work had confirmed these patterns in a patient cohort. The study highlights the value of patient-reported outcomes in HS research.